MONTREAL, June 3, 2011 /CNW/ - The Association québécoise de l'HPN (paroxysmal nocturnal hemoglobinuria) is both surprised and dismayed by
yesterday's recommendation by the Institut national d'excellence en santé et services sociaux (INESSS) to not include Soliris on Quebec's public drug insurance plan
drugs list. The President of the Association québécoise de l'HPN, Barry Katsof, cannot understand INESSS' position given the numerous
studies and clinical cases clearly demonstrating that this drug is
saving the lives of people suffering from this ultra-rare blood
"In terms of efficiency, Soliris has been proven not only to save the
lives of PNH patients, but also to allow those who receive the
treatment to lead active and productive lives, and return to having a
normal life expectancy," said Katsof. "As for the budgetary impact, it
is negligible given the rarity of the disease and the very small number
of patients who may require access to Soliris through the public drug
According to Dr. David Roy, director of the research laboratory in
ethics and aging of the Research Center of the University Geriatrics
Institute of Montreal, INESSS' recommendation on Soliris has created a
fundamental inequity among PNH patients. "The direct consequence of
this recommendation is that it established an inequity between patients
suffering from PNH, because those who do not have the financial and
social resources cannot have access to this life saving treatment."
Dr. Roy added that it would have been reasonable and equitable for the
government to fund the drug, as 26 other industrialized countries
already do, according to three criteria. "Recent studies prove Soliris'
efficacy (Kelly et al.) in curbing high morbidity and premature
mortality, and only a very small number of Quebecers patients are
asking government for access to this treatment."
This funding refusal from INESSS has serious implications for patients
with PNH, as they now face the uncertainty around their future access
to treatment. Moreover, this refusal creates additional barriers in the
process to access Soliris, which already requires considerable efforts
for patients given the provisions under public drug insurance.
To date, less than twenty patients are suffering from PNH in Quebec.
Unfortunately, a small number of patients are still waiting for access
to Soliris. Some have been luckier than others, like Gisèle Sauriol who
has been living with the disease for 15 years. "Four months ago, with
the help of the Association and the RAMQ, my insurance company gave me access to Soliris, a treatment that
allows me to fight the disease and live a normal life. The effect of
the drug was immediate and I quickly saw positive results. My only wish
is for all patients suffering from PNH in this province to have access
to this life-saving medication that gave me back a healthy quality of
life," declared Ms. Sauriol.
Soliris, available since 2009 in Canada, is the first and only treatment
for PNH that allows a patient's life expectancy to return to that of a
healthy person1. PNH is a very rare, progressive and fatal acquired disease that
affects the blood and major organs. It develops without warning,
usually when patients are in the prime of their lives. It is
characterized by haemolysis (the destruction of red blood cells) which
can lead to life-threatening blood clots, kidney disease, pulmonary
hypertension and other catastrophic consequences. Without treatment,
approximately one‐third of PNH patients do not survive more than five
years and about half die within 10 years from the time of diagnosis.
About the Association québécoise de l'HPN
The Association québécoise de l'HPN is a not-for-profit Canadian organization formed in 2009. The mission
of the organization is to connect Canadians affected by Paroxysmal
Nocturnal Haemoglobinuria and advocate best possible care for patients.
The organization also provides support to caregivers, and works to
increase awareness and understanding of PNH.
1 Kelly RJ, Hill A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M,
Mitchell LD, Cohen DR, Gregory WM, Hillmen P. Long term treatment with
eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy
and improved survival. Blood. Prepublished April 1, 2011; DOI
SOURCE Association québécoise d'hémoglobinurie paroxystique nocturne
For further information:
Cohn & Wolfe | Montreal
514-845-2257, ext. 4224